Product Images Rivastigmine Transdermal System

Layer 1, Layer 2, Layer3, Layerd, and Dimple Dimple are available. It is not clear what these layers and dimple represent.*

This appears to be a chart showing the concentration of Rivastigmine in ng/mL for three different dosages (13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours) and the number of participants (n) in each group (19, 22, and 22 respectively).*

This appears to be a statistical analysis output, with LS mean differences and improvements measured at 8, 16, and 24 weeks of treatment using the Rivastigmine Transdermal System in both 15 cm² and 5 cm² forms. The output includes p-values for each measure of improvement and mentions a statistical significance level of 0.05. Therefore, this is likely a summary of a clinical trial evaluating the effectiveness of these two forms of the drug delivery system.*

This is a statistical analysis of the effectiveness of the Rivastigmine Transdermal System 15 cm and 5 cm in improving clinical symptoms over a period of 8-16 weeks of treatment, with the results displayed on a graph. The text includes LS means, standard errors, and P values to indicate statistical significance.*

This appears to be a list of body parts, which includes the left or right upper arm, left or right side of the chest, left or right upper back, and left or right lower back. It is unclear what "LENGE", "Z", and "Lk" refer to, as they are likely non-English characters created by the program.*

This text appears to be a set of instructions to dispose of a patch. It suggests folding the sticky sides of the patch together, placing it into an empty pouch, and then disposing of it in the trash. The instructions also caution to keep the pouch away from children and pets.*

This is a description of a medication called Rivastigmine Transdermal System which comes in a package of 30 systems. Each patch is 5cm and contains 9mg of Rivastigmine. The patch delivers a 4.6mg dosage every 24 hours. The inactive components are acnic adhesive applied to a flexiole polymeres backing film, acrylates copolymer, and silicone adhesive. The package includes instructions for the dosages and administration, and how to discard the used patches safely out of the reach of children. The manufacturer is Breckenridge Pharmaceutical Inc.*

This is a set of instructions for the use and disposal of Rivastigmine Transdermal System. The system contains 30 patches and delivers 8.5 to 9.5 mg of rivastigmine every 24 hours. The old patch should be removed and discarded safely out of the reach of children every day. If the patch is damaged or shows signs of tampering, it should not be used. The inactive components of the patch include acrylic adhesive, copolymers, and silicone adhesive. For more information, visit the website or call the provided phone number.*

This is a medication instruction for Rivastigmine Transdermal System, which contains 30 systems with 13.3 mg Rivastigmine delivered every 24 hours. The instruction provides information on how to use and discard the patch safely. Users must discard the old patch and apply a new one every 24 hours. Inactive components include acrylates copolymer, silicone adhesive, and acrylic adhesive applied to a flexible polymer backing film. The medication should be kept out of reach of children and stored at 25°C (77°F). The instructions do not offer details on why the medication is used.*